[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ben-Gurion University of the Negev\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":162},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,81,106,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100648638","rewiring-chronic-pain-100648638",false,"NCT07724808","Rewiring Chronic Pain","Rewiring Chronic Pain: Cognitive & Somatic Therapy Meets Neuroscience","Inclusion Criteria:\n\n* Age 20-70 years\n* Chronic pain lasting over 3 months, including chronic pain conditions such as fibromyalgia and complex regional pain syndrome (CRPS)\n* Average pain intensity ≥4 on a 0-10 scale\n* Stable medication regimen for at least 4 weeks prior to treatment initiation\n* Hebrew language fluency\n* Provision of informed consent, including consent for video recordings\n\nExclusion Criteria:\n\n* Current participation in other pain-related psychotherapy\n* Pregnancy\n* Substance abuse, including deviations from prescribed medication use\n* Change in medication or dosage in the 4 weeks preceding treatment\n* Diagnosed active cancer\n* Dementia\n* Severe depression (BDI-II score \\> 29)\n* Moderate cognitive impairment based on the Montreal Cognitive Assessment (MoCA)\n* Current or past diagnosis of schizophrenia, psychosis, bipolar disorder, multiple personality disorder, or dissociative identity disorder\n* Inability to undergo MRI as determined by MRI safety screening (e.g., claustrophobia, metal in body such as vascular clips, pacemakers, or certain cochlear implants)","ALL","20 Years","70 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study examines the effectiveness of a brief psychological intervention for chronic pain treatment, as well as the psychological and neurophysiological mechanisms associated with changes in pain intensity.\n\nParticipants with chronic pain will be randomly assigned to one of three groups: two types of brief psychological interventions and a treatment-as-usual control group. Throughout the study, participants will attend a series of therapeutic sessions, complete questionnaires, undergo brain measurements (EEG and MRI), and participate in physiological monitoring using a smartwatch.\n\nThe study aims to investigate which cognitive and physiological changes occur during the intervention, and whether early markers can be identified that may predict improvement in pain following this type of treatment. In addition, differences between cognitive and somatic components of the intervention will be examined to better understand which elements contribute to clinical change, and to determine whether knowledge alone is sufficient or whether participants must undergo a bodily experience in order to produce changes in pain levels.\n\nThe goal of the study is to improve understanding of the mechanisms underlying chronic pain and responses to psychological treatments, and to contribute to the development of more personalized, effective treatments with minimal side effects in the future.",[27,28,29],"Full PRT","Partial PRT (Non Somtic)","Treatment as Usual",[31,32,33,34,35,36,37],"chronic pain","resting-state fMRI","Pain Reprocessing Therapy (PRT)","naturalistic neuroimaging","Network Based Statistic (NBS)","functional connectivity","fMRI","NOT_YET_RECRUITING","2026-07-20",{"date":41,"type":42},"2026-07-24","ACTUAL",{"date":44,"type":21},"2026-10-01",{"date":46,"type":21},"2029-12",{"name":48,"class":49},"Ben-Gurion University of the Negev","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":50},"100495108","examining-the-effectiveness-of-two-behavioral-interventions-for-sleep-problems-in-infants-100495108","NCT05726890","Examining the Effectiveness of Two Behavioral Interventions for Sleep Problems in Infants","Early Childhood Insomnia: Underlying Mechanisms of Intervention Effects of the \"Bedtime Checking\" and the \"Standard Checking\" Methods","Inclusion Criteria:\n\n* Early-childhood insomnia according to DSM-5 criteria\n* The parents wish to sleep independently from the child and would like the infant to need as little help as possible to fall asleep or stay asleep\n* Two-parent, Hebrew-speaking families.\n* Infants born at term (gestational age \\> 36 weeks)\n\nExclusion Criteria:\n\n* Infants and parents with significant physiological sleep problems (e.g., sleep apnea)\n* Infants and parents with any chronic health problems (based on self-report).","9 Months","18 Months",{"count":61,"type":21},270,[24],"Behavioral insomnia of childhood affects 15-30% of infants. Behavioral interventions, based on limiting parent-child bedtime and nighttime interactions, are effective in significantly improving infant sleep problems. However, the implementation of these interventions frequently encompasses significant infant crying and parental distress that deter many parents. Research on gradual sleep interventions that involve a lower \"dose\" of parent-infant separation, and thus may be more acceptable by parents, has so far been sparse. The proposed study aims to advance research in this area through systematically studying the processes through which parent and infant factors impact treatment outcomes of a behavioral intervention method that involves parent-infant separation only at bedtime (\"bedtime checking\"), in comparison to an intervention that also directly targets night-wakings (\"standard checking\"\u002F\"graduated extinction\").",[65],"Insomnia",[67,68,69,70,71],"sleep","early childhood insomnia","infant","parent","behavioral sleep interventions","RECRUITING","2026-04-12",{"date":75,"type":42},"2026-04-15",{"date":77,"type":42},"2023-03-09",{"date":79,"type":21},"2028-09-30",{"name":48,"class":49},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100601921","accelerated-rotational-field-deep-tms-for-treating-ocd-100601921","NCT07116785","Accelerated Rotational Field Deep TMS for Treating OCD","A Prospective Double Blind Randomized Controlled Trial to Evaluate the Efficacy and Durability of Accelerated BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) Protocol in Obsessive-Compulsive Subjects","Inclusion Criteria:\n\n* Outpatients\n* Diagnosed as suffering from OCD according to the DSM-V.\n* Subjects with a YBOCS score of \\>20.\n* If on SRI, patient must be maintained on current dosages (with or without additional antidepressant or psychotropic augmentation for treatment of OCD), at a stable therapeutic dosage for at least 2 months prior to study entry and for the duration of the trial.\n* If in CBT, must be in the maintenance stage (i.e., not receiving active training in exposure and response prevention, which is the core component of this treatment). CBT can be with teletherapy but must be for a minimum of ten sessions with a symptom checklist, hierarchy, with exposure and response prevention therapy.\n* Have negative or justified responses by the investigator to all questions listed on the Transcranial Magnetic Stimulation Safety Screening questionnaire (TASS).\n* According to the treating physician the subject is compliant with taking medication, if applicable.\n* Subject is capable and willing to provide informed consent and assent.\n* Willing and able to adhere to the treatment schedule.\n* All comorbid diagnoses have been stable for 3 months and anticipated to be stable for the 3 months treatment duration.\n\nExclusion Criteria:\n\n* Subjects diagnosed as suffering from any other Axis I diagnosis as the primary diagnosis.\n* Comorbid, secondary psychiatric diagnoses are unstable and are likely to require changes in therapeutic regimens even if OCD improves.\n* Present suicidal risk as assessed by the investigator using the Columbia Suicide Severity Rating Scale, brief mental status exam and psychiatric interview or a history of attempted suicide in the past year.\n* History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT and febrile seizures in infancy).\n* Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.\n* History of head injury necessitating cranial surgery or prolonged coma.\n* History of any ferromagnetic of conductive material in the head including the eyes and ears (outside the mouth).\n* Known history of any metallic particles in the eye, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes).\n* History of significant hearing loss.\n* Subjects with significant neurological disorder or insult\n* Substance use disorder within the past 6 months (except nicotine and caffeine and based on the doctor's judgment).\n* Currently participating in another therapeutic clinical study.\n* Suffer from an unstable physical, systemic and metabolic disorder such as unstable blood pressure, unstable blood sugar, or acute, unstable cardiac disease.\n* Subject on high doses of antidepressant or psychotropic medications, which are known to lower the seizure threshold. Subject is currently on Clomipramine.\n* Significant possibility of death within eighteen months of baseline.\n* Planned surgeries that will interrupt the study schedule within four months of baseline.\n* Women who are breast-feeding.\n* Women who are pregnant or with suspected pregnancy.\n* Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.","18 Years",{"count":90,"type":21},50,[24],"A Prospective Double Blind Randomized Controlled Trial to Evaluate the Efficacy and Durability of the BrainsWay Rotational Field Deep Transcranial Magnetic Stimulation (Deep TMS) in Obsessive-Compulsive Subjects",[94],"Obsessive-Compulsive Disorder",[96,97],"Deep TMS","Rotational Field","2025-08-07",{"date":100,"type":42},"2025-08-12",{"date":102,"type":42},"2023-09-19",{"date":104,"type":21},"2028-12-14",{"name":48,"class":49},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":123,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":50},"100601052","treatment-of-adhd-using-high-and-low-frequency-paired-associative-deep-transcranial-magnetic-stimulation-100601052","NCT07105475","Treatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation","Randomized, Sham Controlled Study for the Treatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation","Inclusion Criteria:\n\n* Men and women aged 21-65.\n* Aligned with the diagnosis of ADHD according to the criteria of the DSM-5.\n* Participants taking medication for the treatment of attention deficit hyperactivity disorder will be asked, starting one week before the start of the treatment until the end, to take Ritalin IR 10mg (provided that the taking of the medication will be done at least 8 hours before the start of the treatment or at least one hour after it. This instruction is also valid for taking the medication on the days of the follow-up sessions (4 and 8 weeks from the end of the daily treatment phase). Ritalin is given as the only option because a drug with a short half-life is needed. The dose can be increased up to 20 mg per dose). The choice of this drug is to ensure that changes in brain function\u002Factivity are not the result of the Ritalin medication but of the research intervention.\n* Give their written and oral consent to participate in the study.\n\nExclusion Criteria:\n\n* Additional active psychiatric disorders in Axis I of the DSM-5.\n* Antipsychotic treatment, antidepressants, or mood stabilizers.\n* History of intolerance to TMS.\n* Diagnosis of severe personality disorder according to the DSM-5.\n* Current suicidal tendency.\n* High and uncontrolled blood pressure.\n* History of epilepsy, seizures or febrile seizures.\n* History of epilepsy or seizures in first degree relatives.\n* History of a head injury or major stroke that produced impairment.\n* History of metal in the head (outside the oral cavity).\n* History of surgery involving metal implants or a known history of metal particles in the eye, pacemakers, hearing aid implantation, use of neurostimulators, or any medical pump.\n* History of drug or alcohol addiction.\n* Inability to adequately communicate with the examiner.\n* Participation in another medical study at the time of conducting the experiment or 3 months before it.\n* Inability of the subject to sign a consent form.\n* Pregnancy or not giving a commitment not to get pregnant during the study period or having sex without using contraceptives.","65 Years",{"count":115,"type":21},90,[24],"This study investigates the effects of high and low-frequency paired associative deep transcranial magnetic stimulation (dTMS) on adults with Attention Deficit Hyperactivity Disorder (ADHD). The study aims to explore whether targeting the prefrontal cortex with paired stimulation can improve symptoms of ADHD by balancing cortical arousal between the brain hemispheres. A total of 90 participants with ADHD will be recruited. Participants with ADHD will undergo three weeks of daily TMS treatment, while participants who receive a sham treatment will be included for baseline comparisons. The study will measure electrophysiological, cognitive, and clinical outcomes using a variety of assessments, including EEG, cognitive tests, and CAARS to evaluate the treatment's efficacy.",[119,120,121,122],"Attention Deficit Hyperactivity Disorder","Neurodevelopmental Disorders","Prefrontal Cortex Dysregulation","Cortical Arousal Imbalance",[124,125,126,127,128],"ADHD","Transcranial Magnetic Stimulation (TMS)","Paired Associative Stimulation (PAS)","Prefrontal Cortex","Hemispheric Asymmetry","2025-07-29",{"date":131,"type":42},"2025-08-06",{"date":133,"type":42},"2023-07-19",{"date":135,"type":21},"2028-09-01",{"name":48,"class":49},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":18,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":50},"100579641","short-term-recall-and-reprocess-therapy-for-post-traumatic-stress-disorder-ptsd-100579641","NCT06826937","Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD)","Short Term Recall and Reprocess Therapy for PTSD","Inclusion Criteria:\n\n* • Diagnosis of PTSD with a score of 25 or higher (i.e. severe PTSD) on the Clinician- Administered PTSD Scale (CAPS-5) at screening.\n\n  * Subjects on FDA-approved antidepressants, trazodone, atypical neuroleptic, prazosin, or clonidine may enter the study if they have been on a stable treatment, as determined by the study clinician, for at least 4 weeks prior to randomization. Following randomization, small changes to doses may be allowable at the PI's discretion.\n  * Able to provide written informed consent.\n  * Able to read and write English\u002FHebrew.\n\nExclusion Criteria:\n\n* • Patients with a diagnostic history of bipolar disorder, borderline personality disorder, obsessive-compulsive disorder, schizophrenia or schizoaffective disorder or currently exhibiting psychotic features as determined by the clinical interview; dementia or suspicion thereof, are excluded. Other DSM Axis I disorders are permitted as long as they are not considered primary disorders.\n\n  * Patients with a history of antidepressant-induced hypomania or mania as determined by open-ended psychiatric interview.\n  * Current, ongoing serious suicidal risk as assessed by evaluating.\n  * Moderate severity or greater Substance Use Disorder (excepting Alcohol Use Disorder) during the 3 months prior to randomization, as determined by the SCID.\n  * History of traumatic brain injury (TBI) with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days may be considered if the trauma occurred more than 1 year ago, and no more than minimal symptoms have persisted over the past year.\n  * Any significant history of neurological illness or heart disease.\n  * Any signs of major medical or neurological illness on examination or as a result of ECG screening or laboratory studies.\n  * Any history indicating learning disability or mental retardation.",{"count":145,"type":21},160,[24],"The goal of this clinical trial is to learn if a short-term behavioral intervention, based on imaginal and in-vivo exposure and psychodynamic reprocessing, works on alleviating Post-Traumatic Stress Disorder (PTSD) symptoms in adults. The trial will also learn about patterns of recovery and relapse by following the patients for up to five years. The main questions it aims to answer are:\n\nDoes the reconsolidation-based short-term intervention help alleviate PTSD symptoms? How is it affecting other mental health issues (such as depression, sleep problems, and general functioning)? What is the long-term effect of the intervention? Researchers will compare this behavioral intervention to a waiting list, for up to three months. People on the waiting list will then be able to cross over to the treatment arm as well.\n\nParticipants will:\n\nBe screened by a clinical psychologist Take the week-long intensive behavioral intervention (psychotherapy) Followed at the end of treatment (day 7), at 30 and 90 days, and every 6 months, up to five years.\n\nWearable devices will be used during the week before treatment, during treatment, and up to 30 days following the end of treatment.",[149,150],"PTSD","Post Traumatic Stress Disorder",[152,153,149],"Prolonged Exposure","Massed Therapy","2025-02-09",{"date":156,"type":42},"2025-02-14",{"date":158,"type":42},"2025-01-25",{"date":160,"type":21},"2030-12-31",{"name":48,"class":49},""]